CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
GLPG1690 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03798366
NCT03798366Phase 2Completed
CompareCT.gov

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered GLPG1690 for 24 Weeks in Subjects With Systemic Sclerosis

Lakefront Biotherapeutics NV·interventional·Posted Jan 9, 2019·Updated May 4, 2021

In Brief

A Phase 2 clinical trial evaluating GLPG1690 and Placebo for Systemic Sclerosis. Completed, enrolled 33 participants across 18 sites in 6 countries.

Detailed Summary

The main purpose of the study is to see if GLPG1690 helps (together with the standard of care treatment) in the treatment of the skin and other areas affected by systemic sclerosis. Another aim is to find out how safe/well tolerated GLPG1690 will be and whether there are any side effects. The study will also look at other things, including whether the study drug affects disease progression and also if it changes any aspect of the quality of life.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSystemic Sclerosis
CountriesBelgium, Germany, Italy, Spain, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJan 9, 2019
Enrollment StartJan 14, 2019
Primary CompletionMay 21, 2020
Study CompletionJun 22, 2020
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 7.5 years ago

Interventions

GLPG1690drug

Film-coated tablets of GLPG1690 for oral use.

Placebodrug

Film-coated tablets of GLPG1690 matching placebo for oral use.